Fundraising Fox

Aaron G.L. Fletcher

Investor

Managing Partner at Bios Partners Β· Board director at Actuate Therapeutics Β· Board director at Lung Therapeutics Β· Board director at ONL Therapeutics

Fort Worth, Texas

Writes $100K – $5M checks Β· typically $1.5M

About

Managing director of Bios Partners and founder/president of Bios Research, providing healthcare public equity research. Holds a PhD in biochemistry from Colorado State University and is a visiting professor at Dallas Baptist University with 10+ years in biotech/healthcare equity consulting.

ContactΒ· self-published, not guessed

Board director at Actuate Therapeutics

Intro paths

β†’

In turn, Aaron can intro founders to Actuate Therapeutics's investors below.

Co-founders at Actuate Therapeutics

DS
Daniel SchmittExecutive Officer, Director

Board director at Lung Therapeutics

Intro paths

β†’

In turn, Aaron can intro founders to Lung Therapeutics's investors below.

Board director at ONL Therapeutics

Intro paths

β†’

In turn, Aaron can intro founders to ONL Therapeutics's investors below.

Co-founders at ONL Therapeutics

DZDavid Zacks
David ZacksCo-Founder & Chief Scientific Officer

Experience

  1. AbiliTech MedicalBoard Membercurrent2017 β€” present
  2. Cognition TherapeuticsBoard Membercurrent2015 β€” present
  3. Actuate TherapeuticsBoard Membercurrent2015 β€” present
  4. Bios PartnersFounder & General Partnercurrent2014 β€” present
  5. Lung Therapeutics, Inc.Board Membercurrent2014 β€” present
  6. Bios Research, LLCFounder and Presidentcurrent2012 β€” present
  7. Dallas Baptist UniversityVisiting Professor of Biochemistrycurrent2008 β€” present
  8. UT Southwestern Medical CenterPostdoctoral Fellow2008Dallas/Fort Worth Area
  9. Colorado State UniversityPHD Candidate2004 β€” 2007
  10. York CollegeLaboratory Assistant1999 β€” 2003

Skills & more

Private Equity, Management, Teaching, Researcher

From Aaron's professional profile.

Deals Β· 3

Actuate TherapeuticsBoard seat

via Bios Partners Β· filed Mar 2024 Β· $5M raise

Cue BiopharmaBoard seat

via Bios Partners Β· filed Nov 2022 Β· $30M raise

Lung TherapeuticsBoard seat

via Bios Partners Β· filed Apr 2022 Β· $15M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Bios Partners

Network7

Investors connected to Aaron in public investor directories β€” a warm-intro map.

Frequently asked questions

Who is Aaron G.L. Fletcher?
Managing director of Bios Partners and founder/president of Bios Research, providing healthcare public equity research. Holds a PhD in biochemistry from Colorado State University and is a visiting professor at Dallas Baptist University with 10+ years in biotech/healthcare equity consulting.
Where does Aaron G.L. Fletcher work?
Aaron G.L. Fletcher is Managing Partner at Bios Partners and Board director at Actuate Therapeutics and Board director at Lung Therapeutics and Board director at ONL Therapeutics.
What check size does Aaron G.L. Fletcher write?
Aaron G.L. Fletcher typically writes checks of $100K – $5M.
What boards does Aaron G.L. Fletcher sit on?
Aaron G.L. Fletcher holds tracked board seats at Actuate Therapeutics, Cue Biopharma, Lung Therapeutics.
Where did Aaron G.L. Fletcher go to school?
Aaron G.L. Fletcher studied at Colorado State University (Doctor of Philosophy - PhD, Biochemistry); York University - Nebraska (Bachelors of Science).

Same school

Shared employers